Industry
Biotechnology
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
September 28, 2023 | 10:21 am
Portfolio Pulse from Benzinga Insights
September 27, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Insights
September 27, 2023 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
September 27, 2023 | 12:42 pm
Portfolio Pulse from Benzinga Insights
September 26, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2023 | 8:29 pm
Portfolio Pulse from Benzinga Newsdesk
September 26, 2023 | 8:01 pm
Portfolio Pulse from Benzinga Insights
August 21, 2023 | 5:00 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.